# US 2013/0295134 A1 · Recombinant bicistronic flavivirus vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295134 A1
- Document ID: US20130295134A1
- Status: Published application
- Kind: A1
- Application number: 13/942,064
- Filed: 2013-07-15
- Published: 2013-11-07
- Earliest claimed: 2007-01-31
- Assignees: Sanofi Pasteur Biologics, LLC
- Applicants: Sanofi Pasteur Biologics, LLC
- Inventors: Simon DELAGRAVE; Nathan Brown; Harold Kleanthous; Farshad Guirakhoo; Alexander A. Rumyantsev
- Web page: https://patentgrep.com/patent/US20130295134A1

## CPC

- C12N 15/86: Viral vectors
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24143: viral genome or elements thereof as genetic vector
- C12N 2840/203: having an IRES
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.

## Claims

### Claim 1

A method of administering a protein or peptide to a subject, the method comprising administering to the subject a chimeric flavivirus comprising structural sequences of a first flavivirus and non-structural sequences of a yellow fever virus, wherein the genome of said chimeric flavivirus comprises an internal ribosome entry site and a transgene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chimeric flavivirus comprises pre-membrane and envelope sequences of said first flavivirus, and capsid and non-structural sequences of said yellow fever virus.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first flavivirus is selected from the group consisting of Japanese encephalitis, Dengue-1, Dengue-2, Dengue-3, Dengue-4, Murray Valley encephalitis, St. Louis encephalitis, West Nile, Kunjin, Rocio encephalitis, Ilheus, Tick-borne encephalitis, Central European encephalitis, Siberian encephalitis, Russian Spring-Summer encephalitis, Kyasanur Forest Disease, Omsk Hemorrhagic fever, Louping ill, Powassan, Negishi, Absettarov, Hansalova, Apoi, and Hypr viruses.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first flavivirus is a Japanese encephalitis virus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the internal ribosome entry site is located in the 3′-untranslated region of the flavivirus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the flavivirus comprises a deletion within the 3′-untranslated region of the flavivirus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the transgene encodes a vaccine antigen.

### Claim 8 (depends on 7)

The method of claim 7, wherein the vaccine antigen is derived from an infectious agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the infectious agent is an influenza virus.

### Claim 10 (depends on 9)

The method of claim 9, wherein the vaccine antigen is selected from the group consisting of hemagglutinin, neuraminidase, or M2, or an immunogenic fragment thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the M2 vaccine antigen comprises the M2e region of the M2 protein.

### Claim 12 (depends on 7)

The method of claim 7, wherein the vaccine antigen is a tumor-associated antigen.

### Claim at position 13

13-19. (canceled)

### Claim 20

A nucleic acid molecule encoding (i) a chimeric flavivirus comprising structural sequences of a first flavivirus and non-structural sequences of a yellow fever virus, wherein the genome of said chimeric flavivirus comprises an internal ribosome entry site and a transgene, or (ii) a flavivirus, wherein the genome of the flavivirus comprises an internal ribosome entry site and a transgene encoding an influenza antigen or an immunogenic fragment thereof.

### Claim at position 15

21-26. (canceled)
